SYNOPSIS: DAM Capital maintained its buy rating on Strides Pharma Science Limited with a target price of Rs. 1,250 apiece, highlighting strong cash generation, 12 percent revenue CAGR, 17 percent EBITDA growth, and potential valuation re-rating. During Monday’s...
SYNOPSIS: Strides Pharma reported Q2 FY26 revenue of Rs. 1,221 crores, up 9 percent QoQ and 5 percent YoY, with net profit rising 24 percent QoQ to Rs. 131.5 crores and strong EBITDA margin expansion. During Friday’s trading session, shares of a global pharmaceutical...
Search Topic or Keyword
Easiest Stock Screener Tool!
Best stock discovery tool with +130 filters, built for fundamental analysis. Profitability, Growth, Valuation, Liquidity, and many more filters. Search Stocks Industry-wise, Export Data For Offline Analysis, Customizable Filters.
